Senior Member Pale_Rider Posted July 31, 2010 Senior Member Share Posted July 31, 2010 Some Histogen updates. If you ask me, this firm looks like it means a serious business. Renowned Dermatologist Dr. Neil Sadick Joins Histogen Scientific Advisory Board Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, today announced that prominent dermatologist and researcher Dr. Neil Sadick has joined the Company's Scientific Advisory Board. As a member of the Company's SAB, I look forward to contributing to the development of Histogen's near-term applications, particularly in the areas of cosmetic surgery and hair restoration where these next-generation products can have a large impact. San Diego, CA (PRWEB) July 22, 2010 Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, today announced that Dr. Neil Sadick has joined the Company's Scientific Advisory Board. A prominent dermatologist and researcher, Dr. Sadick holds positions as Clinical Professor of Dermatology at Weill Cornell Medical College and President of the Cosmetic Surgery Foundation, in addition to being the founder of Sadick Dermatology, a leading aesthetic medicine practice in New York. He is board certified in Dermatology, Cosmetic Surgery, Internal Medicine, and Hair Transplantation. "We are excited to welcome Dr. Sadick to Histogen's Scientific Advisory Board," said Dr. Gail Naughton, CEO and Chairman of the Board for Histogen. "His clinical and research background and expertise will be invaluable as development and clinical studies of Histogen's dermal filler and hair regrowth applications progress." Dr. Sadick is the recipient of the Jobst Award for Research in Vascular Diseases, American Cancer Society Research Award, American Medical Association's Continuing Medical Education Award, and is a lead research physician for Merck Pharmaceutical, ESC Medical, Jobst Biersdorf, and Aesclepion. He has authored more than 500 peer-reviewed articles, written/edited more than 10 books on cosmetic surgery, hair and vein treatment, and contributed more than 75 medical book chapters. "Histogen's technology, and its numerous applications in aesthetic medicine, are truly unique and exciting," said Dr. Sadick. "As a member of the Company's SAB, I look forward to contributing to the development of Histogen's near-term applications, particularly in the areas of cosmetic surgery and hair restoration where these next-generation products can have a large impact." About Histogen Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products that do not contain embryonic stem cells or animal components. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen has two product families - a proprietary liquid complex of embryonic-like proteins and growth factors, and a human Extracellular Matrix (ECM) material, ExCeltrix. For more information, please visit http://www.histogen.com. Renowned Dermatologist Dr. Neil Sadick Joins Histogen Scientific Advisory Board Link to comment Share on other sites More sharing options...
Senior Member FinHairLoss Posted July 31, 2010 Senior Member Share Posted July 31, 2010 I just want my Fin' hair back Link to comment Share on other sites More sharing options...
Senior Member Pale_Rider Posted December 2, 2010 Senior Member Share Posted December 2, 2010 Money for Histogen Histogen Announces Completion of Series A Financing SAN DIEGO, December 1, 2010 - Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, today announced the successful completion of its Series A financing at $10 million. Among other private investors, Secure Medical, Leonard Lavin, Lordship Ventures and Angus Mitchell brought the round to a close. With its pilot clinical trial for hair regrowth completed, a skincare line launched, and exciting preclinical data in applications including oncology, Histogen has added significant value which was recognized by the Company's new and existing shareholders. In addition, Histogen has recently moved into a new facility that will allow for up-scaled manufacturing for its upcoming clinical trials, and later commercial production. "With the Series A completed, we are excited to build on the momentum Histogen has created over the past two years, and further advance the Company's rich product portfolio," said Gail K. Naughton, Ph.D., CEO and Chairman of the Board for Histogen. "We have made significant strides in several important research areas, advanced partnership discussions, and are on track to reach key value inflection points in 2011." This successful completion follows the announcement of initial Series A financing in May 2008. Simultaneously, Histogen opens its Series B financing, which has been approved up to $23 million. The Series B was opened by Angus Mitchell, and Histogen has already received further commitments toward that round. The Company is scheduled to begin a Phase I/II clinical trial of its Hair Stimulating Complex (HSC) in Singapore in Spring 2011, and hopes to also begin a clinical study of its soluble human extracellular matrix (hECM) for the treatment of carcinomatosis, a rapidly progressing and debilitating cancer, mid-year. About Histogen Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products that do not contain embryonic stem cells or animal components. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen has two product families - a proprietary liquid complex of embryonic-like proteins and growth factors, and a human Extracellular Matrix (ECM) material, ExCeltrix. Histogen - About Histogen - Latest news, upcoming events at Histogen Link to comment Share on other sites More sharing options...
Senior Member brentipold Posted December 2, 2010 Senior Member Share Posted December 2, 2010 (edited) Thought they were suppose to start in November, now their starting the Spring.. hmmmmmmmmmmmmmmm Edited December 2, 2010 by brentipold Link to comment Share on other sites More sharing options...
Senior Member Pale_Rider Posted December 3, 2010 Senior Member Share Posted December 3, 2010 Nope, they are starting at spring because they haven?t got the cash on time to start at November, they told that almost a year ago. Now they have the cash, so they can start as re planned. Folks from Histogen are not asses like ones from Follica so they actually answer your questions. ''Thank you for your interest and message. Histogen's Hair Stimulating Complex (HSC) is currently in clinical trials as an injectable for hair regrowth in Male Pattern Hair Loss. More information, and the latest news from our pilot clinical trial of HSC, can be found on the news section of our website at: Histogen - About Histogen - Latest news, upcoming events at Histogen. Our next clinical trial is scheduled to begin in early 2011 in Singapore. While we don’t expect our product to be launched in the US until the 2015 timeframe, Histogen hopes that we can launch sooner outside the US if our international trials go well. However, that timeframe would also be a few years out. As an estimation, Histogen hopes to get product approval in Asia by mid-2013. Histogen expects that launching the HSC product in the EU will be around the same time as a US product in 2015. As the product progresses through development, Histogen will identify whether trials in the UK/EU are necessary. As for hair loss in women, the Histogen team and hair specialists we work with believe that our product should work in women. While these initial studies are focused on male pattern hair loss, Histogen is considering a small side study for hair loss in women and diffused hair loss. If I can answer any further questions, please feel free to contact me directly at the email below. Best regards, Thomas L Hubka ReGenica Brand Manager Market and Business Analyst, Histogen Inc. 858.526.3108 (office) 619.980.7899 (cell)'' Link to comment Share on other sites More sharing options...
Senior Member Shyguy Posted December 4, 2010 Senior Member Share Posted December 4, 2010 how is histogen's ECM product different from Acell's? Using Propecia since 1997 Using Rogaine Foam once a day since 2012 Using Niazoral 2% once a week since 2012 Link to comment Share on other sites More sharing options...
Senior Member Pale_Rider Posted December 31, 2011 Senior Member Share Posted December 31, 2011 Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia - Full Text View - ClinicalTrials.gov Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now